Cargando…
Trial Watch: Toll-like receptor agonists for cancer therapy
Toll-like receptors (TLRs) have long been known for their ability to initiate innate immune responses upon exposure to conserved microbial components such as lipopolysaccharide (LPS) and double-stranded RNA. More recently, this family of pattern recognition receptors has been attributed a critical r...
Autores principales: | Vacchelli, Erika, Eggermont, Alexander, Sautès-Fridman, Catherine, Galon, Jérôme, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782517/ https://www.ncbi.nlm.nih.gov/pubmed/24083080 http://dx.doi.org/10.4161/onci.25238 |
Ejemplares similares
-
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy
por: Galluzzi, Lorenzo, et al.
Publicado: (2012) -
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2012) -
Trial Watch: Toll-like receptor agonists in oncological indications
por: Aranda, Fernando, et al.
Publicado: (2014) -
Trial watch: Oncolytic viruses for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013) -
Trial watch: Monoclonal antibodies in cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013)